Segal Institute For Clinical Research Proudly Participates In Phase III Efficacy Trial Of Long-Acting Treatment Opioid Dependence

Three Principal Investigators from Segal Institute participate in hopes of helping to bring impacting results to people with opioid addiction.

MIAMI--(BUSINESS WIRE)--Segal Institute for Clinical Research has three Principal Investigators currently participating in Braeburn Pharmaceuticals and Camurus’ Phase 3 efficacy Trial of Long-acting Treatment for Opioid Dependence. The first patient has been randomized in the Phase 3 efficacy trial of CAM2038 in opioid-dependent patients.

“CAM2038 will give physicians the ability to specialize treatment based on patients’ needs and goals by providing both monthly and weekly dosing options.”

CAM2038 medications are designed for long-acting weekly and monthly administration. This randomized, double blind, active-controlled Phase 3 trial is part of the registration program for CAM2038, which includes two additional recently started trials; a Phase 2 opioid blockade study and a long-term safety trial.

Opioid addiction has become an epidemic in the U.S. this past decade, yet it’s under-recognized and only a few medicines are in development for its treatment. Opioid addiction is a chronic, relapsing disease that can lead to overdose and death. The Center for Disease Control and Prevention (CDC) reported that opioid related overdose deaths hit a record high in the U.S. of almost 29,000 in 2014, corresponding to nearly 80 deaths each day.

“The success of this trial has the potential to bring a paradigm shift in the way people with opioid dependence are treated,” said Segal Institute’s own Dr. Rishi Kakar. “CAM2038 will give physicians the ability to specialize treatment based on patients’ needs and goals by providing both monthly and weekly dosing options.” Dr. Kakar’s site was the first on this study to randomize a subject.

For more information on this release, contact Kristen Farr at 305-722-8444 or via email at kfarr@segalinstitute.com.

About Segal Institute for Clinical Research
Segal Institute for Clinical Research is a consortium of research sites specializing in psychiatric, neurological, addiction, medical and women’s health clinical trials. A 60-plus staff of full-time Principal Investigators, Sub-Investigators, coordinators, research assistants and Master’s- and Doctorate-level raters conducts clinical trials in outpatient, inpatient, nursing homes, and sleep laboratories. Segal Institute is currently conducting Phase I-IV research trials in 9 different sites in South Florida and South Carolina. Integral to Segal Institute’s success is its centralized operations consisting of quality assurance and improvement managers, rater calibration specialists, recruiters, advertising coordinators, contract managers and call-center.